In our study, targeting IL‐1β in TAMs synergistically with anti‐PD‐1 antibodies improved immune infiltration in malignant PCa with favorable therapeutic effects on the basis of conventional ADT. The gene discussed is IL1B; the disease is posterior cortical atrophy.